Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, announced that it is temporarily postponing its IPO due to plans to conform Phase 3 protocol for the drug (torezolid phosphate) to accomodate new draft guidance recently issued by the FDA. The San Diego, CA-based biotech, which was founded in 2004 and posted $5 million in revenue from federal funding last year, had planned to raise $78 million in its IPO. Credit Suisse, Piper Jaffray and Canaccord Adams were set to be the lead underwriters on the deal, which was scheduled to price on Monday, March 15.